Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy.
about
The Potential Role of Kallistatin in the Development of Abdominal Aortic AneurysmKallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakageKruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression.Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family.Angiogenesis in diabetes and obesityPlasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescentsAntiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway.Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathwayIncreased serum kallistatin levels in type 1 diabetes patients with vascular complicationsAntagonizing Wnt pathway in diabetic retinopathy.Protective Role of Kallistatin in Vascular and Organ Injury.SERPINA3K induces apoptosis in human colorectal cancer cells via activating the Fas/FasL/caspase-8 signaling pathway.Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: Relation to carotid intima media thickness.
P2860
Q26741231-2866DA4C-727F-4BFF-8F81-6A91326A15BDQ28577418-2B4E9E4B-D211-48D4-8A9E-588071710482Q33512668-7661E0DB-E2A5-4AC4-85C5-7D309DB1FDEFQ33859420-05E4F167-415E-49A0-8CA0-0E58596D14B5Q35153884-CE3D34C6-C710-431B-9E4B-40364E13C867Q37133031-1BFB6484-2E2E-4221-8CD5-1B2A33841576Q37333523-1659B2CE-5E1E-47C3-91FA-94B56343B628Q40988610-EEFAC5B3-74D3-4663-B089-ED7A4AF913DAQ42034969-1357BD97-1931-4ADA-A739-8F6DFB94342FQ42149497-58C80323-7CEC-4E6D-B2AA-6574D4CD2D56Q42360588-397BFD69-2527-4A20-8738-9D5DE3C6D03CQ44088705-76F2BD2B-41B9-41ED-B729-DCB9AD616281Q51301114-F29B5EF5-6FF8-4A6E-92BE-8E9FA5F65386
P2860
Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy.
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@ast
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@en
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@nl
type
label
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@ast
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@en
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@nl
prefLabel
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@ast
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@en
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@nl
P2093
P2860
P1433
P1476
Kallistatin in human ocular ti ...... nts with diabetic retinopathy.
@en
P2093
P2860
P304
P356
10.3109/02713689608995143
P577
1996-11-01T00:00:00Z